Shim Clinic Logo

Androgel®, Singapore - Shim Clinic

Androgel®


Latest News

AbbVie wins second AndroGel liability reversal
Mon, 09 Jul 2018 21:02:00 +0800 | PharmaManufacturing.com
A U.S. judge overturned a $140.1 million verdict against AbbVie in a lawsuit by a man who claimed the drugmaker misrepresented the risks of its testosterone replacement drug AndroGel. (Source: PharmaManufacturing.com)

AbbVie wins reversal of $140 million verdict in case over AndroGel risks
Fri, 06 Jul 2018 07:48:54 +0800 | Reuters: Health
A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack. (Source: Reuters: Health)

U.S. judge tosses $140 million verdict against AbbVie in AndroGel case
Fri, 06 Jul 2018 00:46:29 +0800 | Reuters: Health
(Reuters) - A U.S. judge on Thursday overturned a $140 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack. (Source: Reuters: Health)

AbbVie, AndroGel partner owe $448 million in antitrust case: U.S. judge
Sat, 30 Jun 2018 08:38:19 +0800 | Reuters: Health
(Reuters) - A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million. (Source: Reuters: Health)

Abbvie, Androgel partner owe $488 million in antitrust case: U.S. judge
Sat, 30 Jun 2018 06:54:39 +0800 | Reuters: Health
(Reuters) - A U.S. judge on Friday found that Abbvie Inc used sham litigation to illegally prevent generic versions of testosterone gel AndroGel from getting to market and ordered the drugmaker and its partner to pay $488 million. (Source: Reuters: Health)

U.S. Jury Orders AbbVie to Pay $3 Mln in AndroGel Retrial U.S. Jury Orders AbbVie to Pay $3 Mln in AndroGel Retrial
Wed, 28 Mar 2018 01:19:01 +0800 | Medscape Medical News Headlines
A U.S. jury ordered AbbVie to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, though the jury did not find AbbVie strictly liable.Reuters Health Information (Source: Medscape Medical News Headlines)

U.S. jury orders AbbVie to pay $3 million in AndroGel retrial
Tue, 27 Mar 2018 04:36:20 +0800 | Reuters: Health
NEW YORK (Reuters) - A U.S. jury on Monday ordered AbbVie Inc to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, though the jury did not find AbbVie strictly liable. (Source: Reuters: Health)

AbbVie Wins U.S. Trial in Lawsuit Over AndroGel's Risks AbbVie Wins U.S. Trial in Lawsuit Over AndroGel's Risks
Wed, 31 Jan 2018 21:37:22 +0800 | Medscape Diabetes Headlines
A federal jury in Chicago on Friday found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company's testosterone replacement medication AndroGel.Reuters Health Information (Source: Medscape Diabetes Headlines)

AbbVie wins U.S. trial in lawsuit over AndroGel's risks
Sat, 27 Jan 2018 09:18:41 +0800 | Reuters: Health
(Reuters) - A federal jury in Chicago on Friday found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company's testosterone replacement medication AndroGel. (Source: Reuters: Health)

U.S. judge tosses verdict against AbbVie in AndroGel case
Sat, 23 Dec 2017 04:06:21 +0800 | Reuters: Health
(Reuters) - A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel. (Source: Reuters: Health)


Related Concepts


Private & Confidential Service